Related Experiment Videos
New antiarrhythmic drugs
P F Nestico1, J Morganroth, L N Horowitz
1Likoff Cardiovascular Institute, Hahnemann University, Philadelphia.
Drugs
|March 1, 1988
Summary
New antiarrhythmic drugs offer improved options for treating ventricular arrhythmias. This review compares new and conventional agents to guide clinical selection for better patient outcomes.
Area of Science:
- Pharmacology
- Cardiology
- Clinical Medicine
Background:
- Ventricular arrhythmias present ongoing treatment challenges.
- Advances in antiarrhythmic drug development offer new therapeutic avenues.
Purpose of the Study:
- To review and compare new and conventional antiarrhythmic drugs.
- To provide a basis for selecting drug therapy for ventricular arrhythmias.
Main Methods:
- Literature review of electrophysiological, pharmacokinetic, and safety data.
- Comparison of new agents (mexiletine, tocainide, flecainide, etc.) with conventional agents (quinidine, lidocaine, etc.).
Main Results:
- New agents possess diverse pharmacokinetic and electrophysiological profiles.
- Data on efficacy and safety are summarized for informed comparison.
Conclusions:
- Clinicians can use this data to develop algorithms for selecting antiarrhythmic therapy.
- Rational drug selection can improve the management of ventricular arrhythmias.